At the news
? BULLISHIMPACT 8/10 8-K filed Jun 17, 2026 at 07:10 ET
uniQure announced that the FDA has agreed the 3-year analysis from the Phase I/II study of AMT-130 in Huntington's disease can serve as the primary basis of a BLA for accelerated approval. The company intends to submit the BLA in Q3 2026. This is a major regulatory milestone for a gene therapy targeting a currently untreatable neurodegenerative disease with no approved disease-modifying therapies, de-risking the path to market for a pivotal pipeline asset.
- FDA communicated during a Type B meeting that 3-year Phase I/II data are acceptable as primary basis for BLA for accelerated approval of AMT-130 in Huntington's disease.
- Company plans to submit the BLA in the third quarter of 2026.
- FDA seeks alignment on confirmatory study design prior to BLA submission, including consideration of a concurrent standard-of-care control instead of a sham procedure.
- AMT-130 has RMAT, Breakthrough Therapy, and Fast Track designations from the FDA.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access